open access

Vol 2, No 4 (2005)
Review paper
Published online: 2006-02-21
Get Citation

Risperidone. What is the direction of its development?

Bartosz Łoza, Mariusz Bartyzel, Wojciech Matysiewicz, Sanjeev Varghese
Psychiatria 2005;2(4):195-201.

open access

Vol 2, No 4 (2005)
Prace poglądowe - nadesłane
Published online: 2006-02-21

Abstract

Risperidone is approved by FDA for treatment of schizophrenia (1993) or to treat bipolar I (2003) manic or mixed episodes alone or in combination with mood stabilizers, such as lithium or valproate. We’ve done an evaluating review of the various research works looking for some of its new clinical indications. Risperidone as the whole atypical antipsychotic class is being prescribed more and more for off-label indications such as pervasive/autistic developmental disorders in children and adults, behavioral and psychological symptoms of dementia, bipolar spectrum disorders, augmenting SSRIs to treat refractory major depression, to treat anxiety disorders like panic, OCD, and PTSD, borderline personality, Tourette’s syndrome and stuttering. Epidemiological studies suggest a relatively decreased risk of treatment-emergent metabolic adverse events in patients treated with risperidone such as obesity, hyperglycemia, diabetes mellitus, hypercholesterolemia, and hypertriglyceridemia. Side effect profile (mostly hyperprolactinemia and extrapyramidal symptoms) is low at the low dosages (not exceeding 4-6 mg).

Abstract

Risperidone is approved by FDA for treatment of schizophrenia (1993) or to treat bipolar I (2003) manic or mixed episodes alone or in combination with mood stabilizers, such as lithium or valproate. We’ve done an evaluating review of the various research works looking for some of its new clinical indications. Risperidone as the whole atypical antipsychotic class is being prescribed more and more for off-label indications such as pervasive/autistic developmental disorders in children and adults, behavioral and psychological symptoms of dementia, bipolar spectrum disorders, augmenting SSRIs to treat refractory major depression, to treat anxiety disorders like panic, OCD, and PTSD, borderline personality, Tourette’s syndrome and stuttering. Epidemiological studies suggest a relatively decreased risk of treatment-emergent metabolic adverse events in patients treated with risperidone such as obesity, hyperglycemia, diabetes mellitus, hypercholesterolemia, and hypertriglyceridemia. Side effect profile (mostly hyperprolactinemia and extrapyramidal symptoms) is low at the low dosages (not exceeding 4-6 mg).
Get Citation

Keywords

risperidone; schizophrenia; psychopharmacology

About this article
Title

Risperidone. What is the direction of its development?

Journal

Psychiatria (Psychiatry)

Issue

Vol 2, No 4 (2005)

Article type

Review paper

Pages

195-201

Published online

2006-02-21

Bibliographic record

Psychiatria 2005;2(4):195-201.

Keywords

risperidone
schizophrenia
psychopharmacology

Authors

Bartosz Łoza
Mariusz Bartyzel
Wojciech Matysiewicz
Sanjeev Varghese

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl